Efficacy and safety of Cortexin as additional therapy in patients with depressive disorder
Schastnyy ED · 2026 · Zh Nevrol Psikhiatr Im S S Korsakova 126(2):92-96. PMID 41782536
What does this source report?
Reports differences in depression, social-function and adverse-effect ratings between treatment groups.
- Population and setting
- 98 patients with depression; 48 adjunctive Cortexin and 50 antidepressant-only, 28 days
- Evidence type
- Human comparative study
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Randomization and masking are not established in the accessible abstract.
- Short adjunctive study; not evidence for self-treatment or replacing standard psychiatric care.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-29. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Schastnyy ED. Efficacy and safety of Cortexin as additional therapy in patients with depressive disorder Zh Nevrol Psikhiatr Im S S Korsakova 126(2):92-96. PMID 41782536 2026.
Molekul research summary: https://molekul.io/research/bio-41782536. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry